DiaSorin Inc

Stillwater, MN, United States

DiaSorin Inc

Stillwater, MN, United States
SEARCH FILTERS
Time filter
Source Type

PMR estimates that kits for DNA and RNA sample preparation would account for around 60% market share in 2017. However, this product type segment is expected to witness a slight decline in its market share by 2025-end. Although kits will experience a decline in their market share, they are estimated to hold the largest market share in the global DNA and RNA sample preparation market during the forecast period. Workstations are expected to exhibit the fastest growth at 5.8% CAGR through 2025. The global DNA and RNA sample preparation market is projected to register a steady growth at 5.5% CAGR during the forecast period. The US$ 1,293.6 Mn market is estimated to reach US$ 2,090.2 Mn through 2025. Investment in basic research, particularly by academic & research institutes, since past several years have led to solid understanding of fundamental pathways. Through this, various proteins implicated in disease development are either up-regulated or down-regulated. In addition, growing requests by researchers for complex products is an evidence of improvement in understanding basic pathways and discovering new pathways. These factors lead to greater knowledge of cellular pathways, which in turn are estimated to fuel the demand for DNA and RNA sample preparation in the near future. A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/3211 Technological advancements in nucleic acid preparation processes have driven a greater demand for high quality kits, reagents, and associated products. Technological advancements in the methods of DNA and RNA sample preparation, global agreement between leading research institutes for boosting research activities in molecular biology field, soaring demand for modern extraction techniques, and technological advancements in analytical instruments are some major factors driving the market growth. However, increasing inclination of preferences for premium products, owing to their higher quality as compared to standard reagents and products, is expected to restrain the growth of the global DNA and RNA sample preparation market. Hospitals to be Second-most Lucrative End User by 2025-End Academic and research institutes are expected to be the most lucrative end user in the global DNA and RNA sample preparation market through 2025. This segment is expected to exhibit 5.9% CAGR during the forecast period. Hospitals are expected to be the second most lucrative end user segment in the overall market. Based on applications, research applications are expected to remain dominant in the global DNA and RNA sample preparation market during the forecast period. Clinical testing, following research applications, are expected to exhibit 5.4% CAGR through 2025. North America is estimated to be the largest region for DNA and RNA sample preparation market, and is expected to account for more than 40% market share by 2025 end. Although Europe is expected to be the second-most lucrative region for the market, Asia Pacific is estimated to exhibit a comparatively faster growth during the forecast period. Key players in the global DNA and RNA sample preparation market include Agilent Technologies, Inc., Becton Dickinson and Company, Bio-Rad Laboratories, Inc., DiaSorin S.p.A., F. Hoffmann-La Roche Ltd., Illumina, Inc., PerkinElmer, Inc., QIAGEN, Sigma-Aldrich Corporation, Tecan Group AG, and Thermo Fischer Scientific, Inc. DNA & RNA Sample Preparation Market Report 2017-2025 is available for $4900 (Single User License) @ http://www.persistencemarketresearch.com/checkout/3069 Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.


PMR estimates that kits for DNA and RNA sample preparation would account for around 60% market share in 2017. However, this product type segment is expected to witness a slight decline in its market share by 2025-end. Although kits will experience a decline in their market share, they are estimated to hold the largest market share in the global DNA and RNA sample preparation market during the forecast period. Workstations are expected to exhibit the fastest growth at 5.8% CAGR through 2025. The global DNA and RNA sample preparation market is projected to register a steady growth at 5.5% CAGR during the forecast period. The US$ 1,293.6 Mn market is estimated to reach US$ 2,090.2 Mn through 2025. Investment in basic research, particularly by academic & research institutes, since past several years have led to solid understanding of fundamental pathways. Through this, various proteins implicated in disease development are either up-regulated or down-regulated. In addition, growing requests by researchers for complex products is an evidence of improvement in understanding basic pathways and discovering new pathways. These factors lead to greater knowledge of cellular pathways, which in turn are estimated to fuel the demand for DNA and RNA sample preparation in the near future. A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/3211 Technological advancements in nucleic acid preparation processes have driven a greater demand for high quality kits, reagents, and associated products. Technological advancements in the methods of DNA and RNA sample preparation, global agreement between leading research institutes for boosting research activities in molecular biology field, soaring demand for modern extraction techniques, and technological advancements in analytical instruments are some major factors driving the market growth. However, increasing inclination of preferences for premium products, owing to their higher quality as compared to standard reagents and products, is expected to restrain the growth of the global DNA and RNA sample preparation market. Hospitals to be Second-most Lucrative End User by 2025-End Academic and research institutes are expected to be the most lucrative end user in the global DNA and RNA sample preparation market through 2025. This segment is expected to exhibit 5.9% CAGR during the forecast period. Hospitals are expected to be the second most lucrative end user segment in the overall market. Based on applications, research applications are expected to remain dominant in the global DNA and RNA sample preparation market during the forecast period. Clinical testing, following research applications, are expected to exhibit 5.4% CAGR through 2025. North America is estimated to be the largest region for DNA and RNA sample preparation market, and is expected to account for more than 40% market share by 2025 end. Although Europe is expected to be the second-most lucrative region for the market, Asia Pacific is estimated to exhibit a comparatively faster growth during the forecast period. Key players in the global DNA and RNA sample preparation market include Agilent Technologies, Inc., Becton Dickinson and Company, Bio-Rad Laboratories, Inc., DiaSorin S.p.A., F. Hoffmann-La Roche Ltd., Illumina, Inc., PerkinElmer, Inc., QIAGEN, Sigma-Aldrich Corporation, Tecan Group AG, and Thermo Fischer Scientific, Inc. DNA & RNA Sample Preparation Market Report 2017-2025 is available for $4900 (Single User License) @ http://www.persistencemarketresearch.com/checkout/3069 Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.


Colotta F.,DiaSorin SpA | Jansson B.,DiaSorin SpA | Bonelli F.,DiaSorin Inc
Journal of Autoimmunity | Year: 2017

Vitamin D (VitD) is a prohormone most noted for the regulation of calcium and phosphate levels in circulation, and thus of bone metabolism. Inflammatory and immune cells not only convert inactive VitD metabolites into calcitriol, the active form of VitD, but also express the nuclear receptor of VitD that modulates differentiation, activation and proliferation of these cells. In vitro, calcitriol upregulates different anti-inflammatory pathways and downregulates molecules that activate immune and inflammatory cells. Administration of VitD has beneficial effects in a number of experimental models of autoimmune disease. Epidemiologic studies have indicated that VitD insufficiency is frequently associated with immune disorders and infectious diseases, exacerbated by increasing evidence of suboptimal VitD status in populations worldwide. To date, however, most interventional studies in human inflammatory and immune diseases with VitD supplementation have proven to be inconclusive. One of the reasons could be that the main VitD metabolite measured in these studies was the 25-hydroxyVitD (25OHD) rather than its active form calcitriol. Although our knowledge of calcitriol as modulator of immune and inflammatory reactions has dramatically increased in the past decades, further in vivo and clinical studies are needed to confirm the potential benefits of VitD in the control of immune and inflammatory conditions. © 2017 Elsevier Ltd.


Farrell C.,Laverty Pathology | Soldo J.,DiaSorin Inc. | Williams P.,University of Sydney | Williams P.,Royal Prince Alfred Hospital | And 3 more authors.
Clinical Chemistry and Laboratory Medicine | Year: 2012

Background : Clinical laboratories require accurate and precise 25-hydroxyvitamin D (25-OHD) immunoassays to allow comparison of patient results with published decision limits. However, some variation in performance has been found with the previous generation of automated 25-OHD immunoassays. This study assessed the performance of four recently released automated 25-OHD immunoassays against a liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay. Methods : A total of 983 samples from apparently healthy adults, plus 253 samples chosen to challenge the performance of the assays, were analyzed by the latest generation of immunoassays from Abbott, DiaSorin, Roche and Siemens. LC-MS/MS analysis was performed on a random subset of 264 samples. The precision of the immunoassays was assessed over 5 days with samples ranging between 3.0 and 370 nmol/L in concentration. Results : Immunoassays showed significant differences in precision at 25-OHD concentrations of 3.0 - 86.5 nmol/L but all showed acceptable precision at higher concentrations. The DiaSorin assay agreed with LC-MS/MS across the measuring range of samples tested (7.7 - 425 nmol/L). The other assays showed generally good performance, but had some limitations when their performance was challenged with samples with low and high 25-OHD concentrations, heterophilic antibodies or high 25-OHD 2 concentrations. The C3-epimer of 25-OHD was identified in 40.4 % of healthy adults tested and was a source of analytical variance in immunoassays. Conclusions : The latest generation of 25-OHD immunoassays has improved performance compared to previous assays. However, some immunoassays can still give discrepant results and this is most apparent when immunoassays are evaluated with a range of samples that challenge their analytical performance. © 2012 by Walter de Gruyter Berlin Boston.


Farrell C.-J.L.,Laverty Pathology | Soldo J.,DiaSorin Inc. | McWhinney B.,Pathology Queensland | Bandodkar S.,Laverty Pathology | And 4 more authors.
Clinical Chemistry and Laboratory Medicine | Year: 2014

Methods: 25-OHD was measured in 1236 samples using automated assays from Abbott, DiaSorin, Roche and Siemens. A subset of 362 samples had up to three liquid chromatography-tandem mass spectrometry 25-OHD analyses performed. 25-OHD2 recovery, dilution recovery, human anti-animal antibody (HAAA) interference, 3-epi-25-OHD3 cross-reactivity and precision of the automated assays were evaluated.Background: Current automated immunoassays vary significantly in many aspects of their design. This study sought to establish if the theoretical advantages and disadvantages associated with different design formats of automated 25-hydroxyvitamin D (25-OHD) assays are translated into variations in assay performance in practice.Results: The assay that combined release of 25-OHD with analyte capture in a single step showed the most accurate 25-OHD2 recovery and the best dilution recovery. The use of vitamin D binding protein (DBP) as the capture moiety was associated with 25-OHD2 under-recovery, a trend consistent with 3-epi-25-OHD3 cross-reactivity and immunity to HAAA interference. Assays using animal-derived antibodies did not show 3-epi-25-OHD3 cross-reactivity but were variably susceptible to HAAA interference. Not combining 25-OHD release and capture in one step and use of biotin-streptavidin interaction for solid phase separation were features of the assays with inferior accuracy for diluted samples. The assays that used a backfill assay format showed the best precision at high concentrations but this design did not guarantee precision at low 25-OHD concentrations.Conclusions: Variations in design among automated 25-OHD assays influence their performance characteristics. Consideration of the details of assay design is therefore important when selecting and validating new assays.


PubMed | Maria Cecilia Hospital, Irccs Instituto Of Ricerche Famacologiche Mario Negri, Quintiles, DiaSorin Inc. and DiaSorin SpA
Type: | Journal: International journal of cardiology | Year: 2016

Dysregulation of the vitamin D system promotes renal dysfunction and has direct detrimental effects on the heart. Progressive deterioration of renal function is common in patients with chronic heart failure (HF) and is invariably associated with unfavorable outcomes which can be improved by early identification and timely interventions. We examined the relation between two plasma markers of vitamin D metabolism and worsening of renal function (WRF) in a large cohort of patients with chronic HF.Plasma levels of 1,25-dihydroxyvitamin D (1,25(OH)Lower 1,25(OH)The plasma 1,25(OH)


Maters A.W.,Johns Hopkins University | Wright C.V.,Johns Hopkins University | Lee M.T.,Johns Hopkins University | Schwichtenberg G.,DiaSorin Inc. | Detrick B.,Johns Hopkins University
Diagnostic Microbiology and Infectious Disease | Year: 2012

Type-specific serologic tests for human herpes simplex virus (HSV) are critically important for sexually transmitted disease evaluation. We compared the LIAISON® HSV-1 and HSV-2 Type Specific assays relative to an established commercial ELISA. The overall agreement of the chemiluminescence immunoassay versus the ELISA assay was 99.6% (HSV-1) and 100% (HSV-2). The LIAISON® methodology has several advantages. © 2012 Elsevier Inc.


PubMed | University of Minnesota, Catholic University of Louvain and DiaSorin Inc
Type: Journal Article | Journal: PloS one | Year: 2015

Vitamin D deficiency and hyperparathyroidism are common in patients with heart failure (HF). There is a growing body of evidence supporting the role of vitamin D and parathyroid hormone (PTH) in cardiac remodeling and worsening of HF. Lack of reliable automated testing of 1,25-dihydroxyvitamin D (1,25(OH)2D), the biologically active metabolite of vitamin D, has limited its contribution to the prognostic assessment of HF. Here, the association of 1,25(OH)2D and PTH(1-84) levels was evaluated for prediction of cardiovascular death in chronic HF patients.We conducted a single center prospective cohort including 170 chronic HF patients (females n = 36; males n = 134; NYHA II-IV; mean age: 67 years; etiology: ischemic n = 119, dilated cardiomyopathy n = 51; mean LVEF: 23%). The primary outcome was cardiovascular death.Serum levels of 1,25(OH)2D decreased markedly with increased HF severity. Medians were 33.3 pg/mL for NYHA-II patients, 23.4 pg/mL for NYHA-III, and 14.0 pg/mL for NYHA-IV patients (p<0.001). Most patients had levels of 25(OH)D below 30ng/mL, and stratification by NYHA functional class did not show significant differences (p = 0.249). The 1,25(OH)2D to PTH(1-84) ratio and the (1,25(OH)2D)2 to PTH(1-84) ratio were found to be the most significantly related to HF severity. After a median follow-up of 4.1 years, 106 out of 170 patients reached the primary endpoint. Cox proportional hazard modeling revealed 1,25(OH)2D and the 1,25(OH)2D to PTH(1-84) ratios to be strongly predictive of outcomes.1,25(OH)2D and its ratios to PTH(1-84) strongly and independently predict cardiovascular mortality in chronic HF.


Hsu S.A.,Cleveland Clinic | Soldo J.,DiaSorin Inc. | Gupta M.,Cleveland Clinic
Journal of Steroid Biochemistry and Molecular Biology | Year: 2013

Background/methods: A total of 95 human serum specimens, and a 12 specimen precision panel, were measured by 2 automated immunoassays (investigation use only DiaSorin LIAISON® 25 OH Vitamin D TOTAL Assay [LSN], and Siemens ADVIA Centaur® Vitamin D Total (VitD) assay [Centaur]) and the results compared against LC-MS/MS [LCMS] used as the reference method (Esoterix Inc.). For functional sensitivity and precision, 12 serum specimens [range 1.2-148 ng/mL] were run in six replicates [N = 30] or four replicates [N = 20], respectively, for 5 consecutive days. Results: Passing-Bablok fit and Difference plot analysis [N = 92] showed that although both immunoassays had comparable correlation coefficient [r] values to LCMS (0.936 and 0.933), the LSN assay results were statistically equivalent to those given by LCMS (slope 0.93, intercept-2.5), whereas the results of the Centaur assay showed overall significant assay bias compared to LCMS (slope 1.30, intercept-15.8) and this bias was more significant for doses <30 ng/mL by LCMS [bias-30.4%; 95% limits of agreement-72.4% to 11.7%]. For specificity, based on 25-OHD2 and 25-OHD3 levels assessed by LCMS, we divided the specimens into 2 groups, one with detectable 25-OHD2 [Group 1, N = 41] and the other with no detectible 25OHD2 [Group 2, N = 51]. The 2 groups showed comparable correlation coefficient [r] values between the methods, but showed significant differences in slope: Centaur [1.48 with group 1 and 1.18 with group 2] compared to LSN [0.91 with Group 1 and 0.96 with Group 2]. LSN demonstrated better precision [total CV range 5.5-10.0%] compared to Centaur [total CV range 11.0-16.3%]. Functional sensitivity was calculated per EP-17A: 2.15 ng/mL by LSN and 4.57 ng/mL by Centaur. Conclusions: Though there was good overall correlation, substantial bias was present in Centaur. Although LSN had a slope and intercept that was not significantly different than LCMS, Centaur had a significantly higher slope in specimens containing measurable 25-OHD2 levels, a large negative intercept and a significant negative dose bias for doses <30 ng/mL by LCMS, suggesting the Centaur assay would report a higher frequency of patients with apparent vitamin D insufficiency/deficiency at the low end and apparent vitamin D toxicity at the high end compared against LCMS. © 2012 Elsevier Ltd. All rights reserved.


Viaene L.,Catholic University of Leuven | Behets G.J.,University of Antwerp | Claes K.,Catholic University of Leuven | Meijers B.,Catholic University of Leuven | And 4 more authors.
Nephrology Dialysis Transplantation | Year: 2013

Background. Derangements in bone metabolism and vascular calcification (VC) substantially contribute to the accelerated cardiovascular morbidity and mortality in chronic kidney disease (CKD). The Wnt signalling pathway is increasingly recognized to play an important role in bone homeostasis and VC. Circulating levels of the Wnt inhibitor sclerostin are elevated in CKD patients. The present study investigated whether the circulating levels of sclerostin are associated with all-cause mortality in haemodialysis (HD) patients. Methods. We performed a post-hoc survival analysis in 100 prevalent HD patients (68 ± 13 years, 40 male) recruited in 2006 who were prospectively followed for median 637 (8-1000, range) days. Parameters of mineral metabolism including bone-specific alkaline phosphatase (bsAP) and serum sclerostin were determined in spare blood samples collected at baseline. Results. Serum concentrations of serum sclerostin amounted to 110 (82-151) [median (iqr)] pmol/L. Patients with sclerostin levels above median were characterized by older age, higher haemoglobin and creatinine level and lower bsAP concentration. During a median follow-up of 637 days, 31 patients died. Higher circulating sclerostin levels were associated with decreased mortality in prevalent HD patients: unadjusted hazard ratio (HR) 0.51 (0.24-1.06) (P = 0.06); HR adjusted for age and gender for serum sclerostin levels above versus below median was 0.33 (0.15-0.73) (P = 0.006). When bsAP was entered in the Cox regression analysis, it replaced sclerostin in the final model. Conclusions. Our data show that high circulating sclerostin levels are associated with improved survival and suggest that a low bsAP activity may be in the causal pathway. © The Author 2013. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Loading DiaSorin Inc collaborators
Loading DiaSorin Inc collaborators